Practical Reviews

New Cetuximab-Containing Regimen for Anal Cancer Yields Superior Results in HIV

Objective: To determine whether the addition of cetuximab to cisplatin, 5-fluorouracil (5-FU), and radiotherapy (RT) will improve outcome. Design/Methods: A single-arm nonrandomized trial included HIV-positive patients with stage I to stage IIIB anal cancer. Comparison to historical controls was the planned method of outcomes analysis. All patients received cetuximab, cisplatin, 5-FU, and concomitant RT. Results: 45 patients were enrolled. Median age was 47 years, 90% were men, 80% more...
To view this content, you must be a logged in subscriber to
Please Login to view this content.